Antioxidant Capacities of Fruit Extracts of Garcinia indica with Different Assays and Maturity Stages

This study provides a basis and principle for developing an integrated antioxidant assay of Garcinia indica (kokum). Three maturity stages (unripe, medium ripe and fully ripe) of kokum fruit were analyzed for their total phenolic contents (TPC), 1, 1-diphenyl-2-picrylhydrazyl-scavenging ability (DPPH-SC), ferric reducing antioxidant power (FRAP), and oxygen radical antioxidant capacity (ORAC). Significant correlations were obtained for the four assays used (r ranging from 0.380 to 0.767, all p < 0.01). Two-way ANOVA revealed that there were significant effects of maturity stage, and the interaction maturity stages for TPC, FRAP and ORAC, whereas only maturity stage and the interaction term were significant for DPPH-SC activity. Overall, the present results provide basic data for choosing kokum fruits with higher antioxidant activity for direct consumptio

Palm Oil and Rice Bran Oil: Current Status and Future Prospects

The continued demand for edible oils by the ever increasing population makes it pertinent to explore new sources. In this direction, two new edible oils namely palm oil and rice bran oil have been subjected to nutritional and toxicological evaluations of their chemicals constituents. An attempt has been made in this article to assess the acceptability of the two oils based on the various investigations that have been carried out so far

Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome

Background: Atypical hemolytic uremic syndrome (aHUS) is a rare cause of end-stage kidney disease and associated with poor outcomes after kidney transplantation from early disease recurrence. Prophylactic eculizumab treatment at the time of transplantation is used in selected patients with aHUS. We report a retrospective case note review describing transplant outcomes in patients with aHUS transplanted between 1978 and 2017, including those patients treated with eculizumab. / Methods: The National Renal Complement Therapeutics Centre database identified 118 kidney transplants in 86 recipients who had a confirmed diagnosis of aHUS. Thirty-eight kidney transplants were performed in 38 recipients who received prophylactic eculizumab. The cohort not treated with eculizumab comprised 80 transplants in 60 recipients and was refined to produce a comparable cohort of 33 transplants in 32 medium and high-risk recipients implanted since 2002. Complement pathway genetic screening was performed. Graft survival was censored for graft function at last follow-up or patient death. Graft survival without eculizumab treatment is described by complement defect status and by Kidney Disease: Improving Global Outcomes risk stratification. / Results: Prophylactic eculizumab treatment improved renal allograft survival (P = 0.006) in medium and high-risk recipients with 1-y survival of 97% versus 64% in untreated patients. Our data supports the risk stratification advised by Kidney Disease: Improving Global Outcomes. / Conclusions: Prophylactic eculizumab treatment dramatically improves graft survival making transplantation a viable therapeutic option in aHUS